New Dual Stem Cell Therapy Holds Promise for Heart Regeneration

New Dual Stem Cell Therapy Holds Promise for Heart Regeneration

by Adeline Dorcas on  August 10, 2019 at 1:08 PM Health Watch
RSS Email Print This Page Comment bookmark
Font : A-A+

Highlights:
  • Newly developed dual stem cell therapy can repair myocardial infarction (MI) heart effectively
  • The new multipronged approach aimed to concurrently rejuvenate both the muscle cells and vascular systems of the heart by utilizing two types of stem cells
  • Using this new dual stem cell-based treatment, scientists observed significant improvement of heart function and enhancement of vessel formation on a MI heart
Myocardial infarction (MI), also known as a heart attack, affects millions of people across the world. However, currently, available treatments are complex, very risky, and costly. Therefore, a dual stem cell therapy for heart regeneration has emerged as a promising therapeutic option to repair the damaged heart.
New Dual Stem Cell Therapy Holds Promise for Heart Regeneration

As a medical emergency caused by severe cardiovascular diseases, myocardial infarction (MI) can inflict permanent and life-threatening damage to the heart. A joint research team comprising scientists from City University of Hong Kong (CityU) has recently developed a multipronged approach for concurrently rejuvenating both the muscle cells and vascular systems of the heart by utilizing two types of stem cells. The findings give hope to develop a new treatment for repairing MI heart, as an alternative to the existing complex and risky heart transplant for seriously-ill patients.

Show Full Article


What is Myocardial Infarction?

Myocardial infarction (MI) is a fatal disorder caused by a shortage of coronary blood supply to the myocardium. It leads to permanent loss of heart muscle cells (cardiomyocytes, CMs), and scar tissue formation, resulting in irreversible damage to cardiac function or even heart failure. With limited therapeutic options for severe MI and advanced heart failure, a heart transplant is the last resort. But it is very risky, costly and subject to limited suitable donors. Therefore, stem cell-based therapy has emerged as a promising therapeutic option.

Dr. Ban Kiwon, a stem cell biologist from Department of Biomedical Sciences at CityU, has been focusing on developing novel stem cell-based treatments for cardiac regeneration. "Heart is an organ composed of cardiac muscles and blood vessels, where vessels are essential to supply oxygen and energy to the muscles. Since both cardiac muscles and vasculatures would be severely damaged following MI, the therapeutic strategies should focus on comprehensive repair of both at the same time. But so far the strategies only focus on either one," he explains.

In this regard, Dr. Ban and his collaborators, including researchers from Konkuk University, The Catholic University of Korea, Pohang University of Science and Technology, and T&R Biofab in South Korea, have recently developed a multipronged approach. It aimed to concurrently rejuvenate both the heart muscles and the vasculatures by utilizing two major types of stem cells, namely human bone marrow derived mesenchymal stem cells (hMSCs) and cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs).

The hMSCs was employed in the study due to their prominent paracrine activity of secreting good proteins to promote the regeneration of blood vessels and the endothelial cell survival. And the hiPSC-CMs was utilized for their similarities with human primary CMs in terms of the expressions of cardiac-specific genes, structural proteins, ion channels, and more importantly, the spontaneous contraction.

First Study of Two Distinct Stem Cell Effects for Cardiac Repair

While several previous studies described the beneficial effects of either hiPSC-CMs or hMSCs on MI separately, this is the first study to simultaneously examine the effects of these two distinct stem cells in cardiac repair. The researchers have adopted a dual approach, in which the hMSCs and the hiPSC-CMs were delivered via two distinct routes. The hiPSC-CMs were intramyocardially injected directly into border zone of the rat's heart, while the hMSCs-loaded patch was implanted on top of the infarct area, like a bandage.

The results showed that this dual approach led to a significant improvement of cardiac function and enhancement of vessel formation on a MI heart. The implanted hMSC-loaded patch not only provided a micro-environment which enhanced vascular regeneration as expected, but also improved the retention of hiPSC-CMs, ultimately augmenting heart function and restoring the injured myocardium.

Moreover, histological analyses results demonstrated that the implantation of hMSC-loaded patch has promoted the functional maturation of injected hiPSC-CMs. They became more elongated and rectangular in cell shape, appeared to be more organized in order, which were typical morphological characteristics of matured adult CMs. Functional maturation of intramyocardially injected hiPSC-CMs is particularly important. It is because it can reduce potential risk of arrhythmias, meaning irregular heart contraction, which is a major cause of sudden cardiac death.

Application Potential in Cardiac Regeneration and Beyond

"We believe this novel dual approach can potentially provide translational and clinical benefit to the field of cardiac regeneration," said Dr. Ban. "Based on the same principle, the protocol may also be utilized for repairing other organs including brain, liver, and pancreas in which multiple types of stem cells are co-existing." The team is working on follow-up studies in a larger animal model such as pigs. The patent application has been submitted.

The research findings were published in scientific journal Nature Communications, titled "Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction". Dr. Ban, together with Dr. Moon Sung-Hwan from Konkuk University School of Medicine and Professor Park Hun-Jun from The Catholic University of Korea, are the corresponding authors of the paper. The first authors are Park Soon-Jung from Konkuk University School of Medicine, Kim Ri Youn and Ph.D. student Lee Sunghun from CityU and Park Bong-Woo from The Catholic University of Korea.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive